Novatek Pharmaceuticals

Novatek Pharmaceuticals, Inc. was founded based on years of preclinical and initial clinical experience with black cumin and thymoquinone in the treatment of various diseases, recently including preclinical anti-COVID-19 effects, indicating that the TQ formulation may also be active against SARS-CoV-2. The company will closely manage work subcontracted to CROs and CDMOs. We have a clinically trained professional team with extensive experience in both basic and clinical research.We are a company focused on the potential beneficial effects of TQ on the pathophysiology of COVID-19, including its antioxidant, anti-inflammatory, immunomodulatory, epigenetic regulatory, antiviral, anti-COVID-19 docking study, and antiviral activities.